• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物假期与帕金森病的管理

Drug holiday and management of Parkinson disease.

作者信息

Weiner W J, Koller W C, Perlik S, Nausieda P A, Klawans H L

出版信息

Neurology. 1980 Dec;30(12):1257-61. doi: 10.1212/wnl.30.12.1257.

DOI:10.1212/wnl.30.12.1257
PMID:7192805
Abstract

Chronic treatment of parkinsonism with levodopa or levodopa/carbidopa is associated with problems that include dyskinesia, on-off phenomena, hallucinosis, and possible loss of therapeutic efficacy. We studied the effects of a period of transient drug withdrawal (drug holiday) in 16 patients who manifested these complications of chronic levodopa therapy. Patients were evaluated daily before, during, and after the period of drug withdrawal. Eleven of the 16 patients exhibited enhanced motor responsiveness after the holiday and required only half of the initial daily dose for improved motor performance. Most levodopa-induced side effects decreased after the holiday. Hallucinosis was ameliorated in all cases. The frequency of on-off phenomena and myoclonus also diminished. Sensitivity to levodopa-induced dyskinesia was not affected by the drug holiday. Because most patients required lower dosage after the holiday, dyskinesias were no longer present. These observations suggest that parkinsonian patients who suffer complications of chronic levodopa therapy may benefit from a period of drug withdrawal.

摘要

长期使用左旋多巴或左旋多巴/卡比多巴治疗帕金森病会引发一系列问题,包括运动障碍、开关现象、幻觉以及可能出现的治疗效果丧失。我们对16名出现慢性左旋多巴治疗并发症的患者进行了一段短暂停药期(药物假期)的效果研究。在停药期之前、期间和之后,每天对患者进行评估。16名患者中有11名在停药期后表现出运动反应增强,并且仅需初始每日剂量的一半就能改善运动表现。停药期后,大多数左旋多巴引起的副作用有所减轻。幻觉在所有病例中均得到改善。开关现象和肌阵挛的频率也有所降低。药物假期对左旋多巴诱发的运动障碍的敏感性没有影响。由于大多数患者在停药期后需要较低剂量,运动障碍不再出现。这些观察结果表明,患有慢性左旋多巴治疗并发症的帕金森病患者可能会从一段停药期中获益。

相似文献

1
Drug holiday and management of Parkinson disease.药物假期与帕金森病的管理
Neurology. 1980 Dec;30(12):1257-61. doi: 10.1212/wnl.30.12.1257.
2
Complications of chronic levodopa therapy: long-term efficacy of drug holiday.慢性左旋多巴治疗的并发症:药物假期的长期疗效
Neurology. 1981 Apr;31(4):473-6. doi: 10.1212/wnl.31.4.473.
3
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.帕金森病中速释与控释卡比多巴/左旋多巴的比较。一项多中心5年研究。CR首次研究组。
Eur Neurol. 1997;37(1):23-7. doi: 10.1159/000117399.
4
Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.晚期帕金森病患者对左旋多巴/卡比多巴凝胶持续十二指肠输注的长期反应:巴塞罗那登记研究
Parkinsonism Relat Disord. 2015 Aug;21(8):871-6. doi: 10.1016/j.parkreldis.2015.05.014. Epub 2015 May 19.
5
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.晚期帕金森病异动症的抑制。I. 持续静脉注射左旋多巴可改变晚期帕金森病患者异动症产生的剂量反应,但不改变帕金森病症状缓解的剂量反应。
Neurology. 1993 Aug;43(8):1545-50. doi: 10.1212/wnl.43.8.1545.
6
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.降低卡比多巴/左旋多巴的给药频率:双盲交叉研究,比较卡比多巴/左旋多巴每日两次双层制剂(IPX054)与稳定期帕金森病患者每日4次标准卡比多巴/左旋多巴的疗效。
Clin Neuropharmacol. 2009 Jul-Aug;32(4):189-92. doi: 10.1097/WNF.0b013e3181a27fae.
7
Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.帕金森病中速释和控释卡比多巴/左旋多巴:一项为期5年的随机多中心研究。卡比多巴/左旋多巴研究组。
Neurology. 1999 Sep 22;53(5):1012-9. doi: 10.1212/wnl.53.5.1012.
8
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.左旋多巴-卡比多巴肠凝胶空肠输注与左旋多巴-卡比多巴片口服给药治疗日本晚期帕金森病患者的药代动力学、初步疗效及安全性比较
Clin Pharmacokinet. 2015 Sep;54(9):975-84. doi: 10.1007/s40262-015-0265-3.
9
Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.帕金森病左旋多巴治疗的进展:左旋多巴控释剂(卡比多巴和左旋多巴)临床疗效与安全性综述。
Neurology. 2016 Apr 5;86(14 Suppl 1):S13-24. doi: 10.1212/WNL.0000000000002510. Epub 2016 Apr 4.
10
Weekly drug holiday in Parkinson disease.
Neurology. 1981 Nov;31(11):1460-2. doi: 10.1212/wnl.31.11.1460.

引用本文的文献

1
Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility?重新思考帕金森病:多巴胺减少疗法是否具有临床应用价值?
J Neurol. 2024 Aug;271(8):5687-5695. doi: 10.1007/s00415-024-12526-7. Epub 2024 Jun 21.
2
From kitchen to clinic: Pharmacotherapeutic potential of common spices in Indian cooking in age-related neurological disorders.从厨房到诊所:印度烹饪中常见香料在年龄相关性神经疾病中的药物治疗潜力
Front Pharmacol. 2022 Nov 10;13:960037. doi: 10.3389/fphar.2022.960037. eCollection 2022.
3
Changes in dynamic transitions between integrated and segregated states underlie visual hallucinations in Parkinson's disease.
帕金森病患者的视幻觉是由整合态和分离态之间的动态转变变化引起的。
Commun Biol. 2022 Sep 8;5(1):928. doi: 10.1038/s42003-022-03903-x.
4
Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases.下一代个性化医疗:慢性病中克服耐药性的变异性模式的实施。
J Pers Med. 2022 Aug 10;12(8):1303. doi: 10.3390/jpm12081303.
5
Digital Analgesic Comprising a Second-Generation Digital Health System: Increasing Effectiveness by Optimizing the Dosing and Minimizing Side Effects.包含第二代数字健康系统的数字镇痛法:通过优化剂量和最小化副作用提高疗效
J Pain Res. 2022 Apr 13;15:1051-1060. doi: 10.2147/JPR.S356319. eCollection 2022.
6
Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response.数字医用大麻作为市场差异化因素:用于改善反应的第二代人工智能系统
Front Med (Lausanne). 2022 Jan 24;8:788777. doi: 10.3389/fmed.2021.788777. eCollection 2021.
7
Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.左旋多巴诱导的运动障碍:帕金森病、多巴胺的历史回顾,以及研究和治疗的现代进展。
J Neurol. 2022 Jun;269(6):2892-2909. doi: 10.1007/s00415-022-10963-w. Epub 2022 Jan 17.
8
Second-Generation Digital Health Platforms: Placing the Patient at the Center and Focusing on Clinical Outcomes.第二代数字健康平台:以患者为中心并聚焦临床结果。
Front Digit Health. 2020 Dec 3;2:569178. doi: 10.3389/fdgth.2020.569178. eCollection 2020.
9
A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage.一个用于辅助 COVID-19 进展诊断和监测的数字健康平台:一种增强抗病毒反应和减轻免疫介导的靶器官损伤的辅助方法。
Biomed Pharmacother. 2021 Nov;143:112228. doi: 10.1016/j.biopha.2021.112228. Epub 2021 Sep 22.
10
Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases.建立第二代基于人工智能的系统,以改善罕见病患者的诊断、治疗和监测。
Eur J Hum Genet. 2021 Oct;29(10):1485-1490. doi: 10.1038/s41431-021-00928-4. Epub 2021 Jul 19.